NEATO-ROBOTICS
4.9.2020 13:32:20 CEST | Business Wire | Pressemeddelelse
Neato Robotics, en førende leverandør af intelligente robotstøvsugere til hjemmet, har i dag annonceret lanceringen af de nye modeller i deres kvalitetsserie – Neato D10, D9 og D8 – på IFA Berlin 2020. Neato-robotstøvsugere er den ultimative partner inden for rengøring, idet de har den bedste teknologi i klassen, nem indstilling og hardware, der er skabt til at holde.
Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20200904005047/da/
"Vi har kombineret Neatos 15 års erfaring i branchen med kundefeedback og de seneste nyskabelser inden for robotteknologi og kunstig intelligens, og vi er glade for at kunne introducere disse fantastiske nye produkter – vores bedste indtil nu – for hele verden. Neatos nye serie af intelligente robotstøvsugere er unik i design og teknologi, med en førsteklasses brugeroplevelse og en ny MyNeato-app, som viser vores forpligtelse til at gøre hverdagen nemmere med robotteknologi", siger Neatos CEO, Thomas Nedder.
De nye Neato-robotstøvsugere har kvalitet og brugeroplevelse, der er bedst i deres klasse, samtidig med, at deres D-formede design, som er det første af sin art i branchen, har fået et løft. Neato-ejere kan nå fra hjørne til hjørne og fra kant til kant og få en mere komplet rengøring ved at bruge den bredeste børste og den største støvbeholder på markedet. Neato har det første originale HEPA-filter, og Neato D10 opfanger op til 99,97 % allergener og partikler såsom støv og skæl helt ned til 0,3 my. Det har aldrig været nemmere at indstille en Neato, med en Bluetooth-aktiveret tilslutning til wi-fi og effektiviseret sekstrins-proces på vores nye MyNeato-app – den korteste indstillingsproces i branchen – for straks at komme i gang med rengøringen.
Neato D10
Med en køretid på op til 150 minutter, et originalt HEPA-filter til at opfange op til 99,97 % allergener så små som 0,3 my samt den seneste LaserSmartTM LIDAR-baserede teknologi, er Neato D10 ultraydeevnen til den ultimative rengøring.
Neato D9
Neato D9 gør det beskidte arbejde for dig. Med et ultraydende filter i HEPA-stil, der opfanger 99,5 % støv og allergener, en køretid på op til 120 minutter samt Neatos signatur-teknologi, LaserSmartTM , gør Neato rent når og hvor du ønsker det, også når det er mørkt.
Neato D8
Neato D8 leveres med branchens første signaturkvalitet og -teknologi, som du er vant til at forvente fra Neato – som fx den største støvbeholder, ekstra bred børste og den seneste LaserSmartTM -teknologi – med en bedre brugeroplevelse, en køretid på op til 90 minutter og forbedret effektiv rengøring.
Den nye produktserie vil være tilgængelig i efteråret 2020 hos vores detailhandlere i hele Nordamerika, Europa og Japan, samt i USA på NeatoRobotics.com .
Om Neato
Neato Robotics udvikler intelligente robotter til hjemmet for at gøre livet nemmere for folk og løse reelle problemer. Neato er engageret i at skabe en ægte brugerdefineret rengøringsoplevelse, hvor vi sikrer, at robotterne udvikles og tilpasses til forbrugeren. Neato driver innovation med intelligent LaserSmartTM LIDAR-baseret navigation, kortlægning, smart hjemmeopkobling og uovertruffen rengøringsteknologi. Få mere at vide på www.neatorobotics.com .
Se kildeudgaven på businesswire.com: https://www.businesswire.com/news/home/20200904005047/da/
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum
